Longfellow Investment Management Co. LLC Takes Position in AstraZeneca PLC $AZN

Longfellow Investment Management Co. LLC bought a new position in shares of AstraZeneca PLC (NASDAQ:AZN) during the third quarter, Holdings Channel.com reports. The fund bought 49,765 shares of the company’s stock, valued at approximately $3,818,000. AstraZeneca accounts for 0.9% of Longfellow Investment Management Co. LLC’s investment portfolio, making the stock its 17th largest holding.

Several other hedge funds have also bought and sold shares of the business. Chapin Davis Inc. raised its holdings in AstraZeneca by 3.3% during the third quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock worth $291,000 after buying an additional 120 shares during the last quarter. CoreCap Advisors LLC increased its position in shares of AstraZeneca by 30.6% during the third quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock worth $41,000 after acquiring an additional 125 shares in the last quarter. Highline Wealth Partners LLC increased its position in shares of AstraZeneca by 32.0% during the third quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock worth $41,000 after acquiring an additional 129 shares in the last quarter. Traub Capital Management LLC raised its holdings in shares of AstraZeneca by 3.3% in the 3rd quarter. Traub Capital Management LLC now owns 4,115 shares of the company’s stock worth $316,000 after acquiring an additional 130 shares during the last quarter. Finally, Aaron Wealth Advisors LLC lifted its position in AstraZeneca by 0.6% in the 3rd quarter. Aaron Wealth Advisors LLC now owns 21,215 shares of the company’s stock valued at $1,628,000 after acquiring an additional 136 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of recent research reports. Citigroup started coverage on AstraZeneca in a report on Tuesday, January 27th. They set a “buy” rating for the company. Wall Street Zen downgraded AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, January 21st. Morgan Stanley reaffirmed an “overweight” rating and set a $103.00 price objective on shares of AstraZeneca in a report on Wednesday, December 3rd. Finally, Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $95.75.

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at $197.74 on Friday. The business’s fifty day simple moving average is $144.68 and its 200 day simple moving average is $105.45. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. AstraZeneca PLC has a 12 month low of $122.48 and a 12 month high of $212.71. The firm has a market capitalization of $306.68 billion, a P/E ratio of 65.69, a price-to-earnings-growth ratio of 1.59 and a beta of 0.32.

AstraZeneca Dividend Announcement

The business also recently declared a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be issued a $1.595 dividend. This represents a dividend yield of 156.0%. The ex-dividend date of this dividend is Friday, February 20th. AstraZeneca’s payout ratio is 66.26%.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.